DK3142664T3 - Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme - Google Patents
Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme Download PDFInfo
- Publication number
- DK3142664T3 DK3142664T3 DK15792756.7T DK15792756T DK3142664T3 DK 3142664 T3 DK3142664 T3 DK 3142664T3 DK 15792756 T DK15792756 T DK 15792756T DK 3142664 T3 DK3142664 T3 DK 3142664T3
- Authority
- DK
- Denmark
- Prior art keywords
- diagnostication
- compositions
- treatment
- methods
- eye diseases
- Prior art date
Links
- 208000030533 eye disease Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21046—Complement factor D (3.4.21.46)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461993915P | 2014-05-15 | 2014-05-15 | |
| US201462064344P | 2014-10-15 | 2014-10-15 | |
| US201462076162P | 2014-11-06 | 2014-11-06 | |
| US201562157773P | 2015-05-06 | 2015-05-06 | |
| PCT/IB2015/053609 WO2015173786A1 (en) | 2014-05-15 | 2015-05-15 | Compositions and methods for treating and diagnosing ocular disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3142664T3 true DK3142664T3 (da) | 2020-03-09 |
Family
ID=54479391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15792756.7T DK3142664T3 (da) | 2014-05-15 | 2015-05-15 | Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20170079955A1 (da) |
| EP (1) | EP3142664B1 (da) |
| JP (1) | JP6625064B2 (da) |
| DK (1) | DK3142664T3 (da) |
| ES (1) | ES2789849T3 (da) |
| HU (1) | HUE049518T2 (da) |
| WO (1) | WO2015173786A1 (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| BR112018013407A2 (pt) | 2015-12-30 | 2018-12-18 | Kodiak Sciences Inc | anticorpos e conjugados dos mesmos |
| US11610311B2 (en) | 2016-10-13 | 2023-03-21 | Translatum Medicus, Inc. | Systems and methods for detection of ocular disease |
| WO2018119202A1 (en) * | 2016-12-23 | 2018-06-28 | StemBios Technologies, Inc. | Use of somatic stem cells for increasing level of peroxisome proliferator-activated receptor gamma |
| RU2683758C1 (ru) * | 2018-06-27 | 2019-04-01 | Федеральное государственное учреждение "Федеральный исследовательский центр "Информатика и управление" Российской академии наук" (ФИЦ ИУ РАН) | Автоматизированная система анализа ангиографических изображений глазного дна человека |
| EP3706136A1 (en) * | 2019-03-05 | 2020-09-09 | Novartis AG | Computerized systems for prediction of geographic atrophy progression using deep learning applied to clinical imaging |
| EP3990433A4 (en) | 2019-06-25 | 2023-07-26 | Translatum Medicus Inc. | METHODS FOR THE MANUFACTURE OF 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES |
| EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | METHOD FOR TREATING AN EYE DISORDER |
| RU196414U1 (ru) * | 2019-12-23 | 2020-02-28 | Федеральное государственное учреждение "Федеральный исследовательский центр "Информатика и управление" Российской Академии Наук" | Анализатор ангиографических изображений глазного дна человека |
| WO2023200766A1 (en) * | 2022-04-14 | 2023-10-19 | Belite Bio, Inc | Methods, compositions and systems for evaluation of visual function |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005108431A1 (en) * | 2004-05-04 | 2005-11-17 | University Of Kentucky Research Foundation | Methods and compositions for the treatment of ocular neovascularization |
| ITMI20062254A1 (it) * | 2006-11-24 | 2008-05-25 | Acraf | Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca |
| PT2254869T (pt) * | 2008-03-07 | 2017-07-18 | Acraf | Novos derivados de 1-benzil-3-hidroximetilindazole e suas utilizações no tratamento de doenças com base na expressão de cx3cr1 e p40 |
| CA3095012C (en) * | 2012-05-01 | 2023-02-07 | Translatum Medicus Inc. | Methods for treating and diagnosing blinding eye diseases |
-
2015
- 2015-05-15 HU HUE15792756A patent/HUE049518T2/hu unknown
- 2015-05-15 US US15/311,083 patent/US20170079955A1/en not_active Abandoned
- 2015-05-15 WO PCT/IB2015/053609 patent/WO2015173786A1/en active Application Filing
- 2015-05-15 ES ES15792756T patent/ES2789849T3/es active Active
- 2015-05-15 EP EP15792756.7A patent/EP3142664B1/en active Active
- 2015-05-15 JP JP2016567824A patent/JP6625064B2/ja active Active
- 2015-05-15 DK DK15792756.7T patent/DK3142664T3/da active
-
2018
- 2018-05-30 US US15/993,183 patent/US20180338952A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017520527A (ja) | 2017-07-27 |
| ES2789849T3 (es) | 2020-10-26 |
| US20180338952A1 (en) | 2018-11-29 |
| HUE049518T2 (hu) | 2020-09-28 |
| EP3142664B1 (en) | 2019-12-04 |
| JP6625064B2 (ja) | 2019-12-25 |
| WO2015173786A1 (en) | 2015-11-19 |
| EP3142664A4 (en) | 2017-12-13 |
| EP3142664A1 (en) | 2017-03-22 |
| US20170079955A1 (en) | 2017-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3234133T3 (da) | Crispr-baserede sammensætninger og fremgangsmåder til anvendelse | |
| DK3212226T3 (da) | Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser | |
| DK3185876T3 (da) | Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser | |
| DK3129018T3 (da) | Behandling af NAFLD og NASH | |
| DK3317284T3 (da) | Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse | |
| DK3134530T3 (da) | Behandling af hyperbilirubinæmi | |
| DK3450553T3 (da) | Mrna-terapi til behandling af øjensygdomme | |
| DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
| DK3777855T3 (da) | Fremgangsmåder til behandling af fibrotiske sygdomme | |
| DK3224269T3 (da) | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser | |
| DK3119797T3 (da) | Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose | |
| DK3209696T3 (da) | Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom | |
| DK3142664T3 (da) | Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme | |
| DK3144001T3 (da) | Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3394065T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf | |
| DK3189074T3 (da) | Sammensætninger og metoder til behandling og forebyggelse af inflammation | |
| DK3110446T3 (da) | Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme | |
| DK3194564T3 (da) | Trichodermasammensætninger og anvendelsesfremgangsmåder | |
| DK3261644T3 (da) | Sammensætninger og fremgangsmåder til behandling af nethindenedbrydning | |
| DK3319609T3 (da) | Sammensætninger og fremgangsmåder til anvendelse af antibakterielle lægemiddelkombinationer | |
| DK3089971T3 (da) | Forbindelser og fremgangsmåder til anvendelse | |
| DK3164394T3 (da) | Gls1-inhibitorer til behandling af sygdomme | |
| DK3185872T3 (da) | Formulering af testosteron og metoder til behandling hermed |